伊谢珠单抗联合低剂量甲氨蝶呤成功治疗红皮病型银屑病1例，确保持续清除：1例报告。

Q3 Medicine

Case Reports in Dermatological Medicine Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI:10.1155/crdm/8810497

Jennifer Lavina Ngo, Lily Lyralin Tumalad, Patricia Anne Tinio, Rogelio Balagat

{"title":"伊谢珠单抗联合低剂量甲氨蝶呤成功治疗红皮病型银屑病1例，确保持续清除：1例报告。","authors":"Jennifer Lavina Ngo, Lily Lyralin Tumalad, Patricia Anne Tinio, Rogelio Balagat","doi":"10.1155/crdm/8810497","DOIUrl":null,"url":null,"abstract":"Erythrodermic psoriasis (EP) is a severe type of psoriasis that requires immediate and effective treatment to prevent serious complications. Although recommended as first-line treatment for EP, conventional systemic disease-modifying antirheumatic drugs (csDMARDs) such as methotrexate and/or cyclosporine can sometimes be ineffective or undesirable, hence the use of biologics. However, in cases of refractory disease, biologics may be combined with methotrexate to boost efficacy and optimize outcomes without compromising safety and tolerability.","PeriodicalId":9630,"journal":{"name":"Case Reports in Dermatological Medicine","volume":"2025 ","pages":"8810497"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140818/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Case of Erythrodermic Psoriasis Successfully Treated With Ixekizumab Combined With Low-Dose Methotrexate to Ensure Sustained Clearance: A Case Report.\",\"authors\":\"Jennifer Lavina Ngo, Lily Lyralin Tumalad, Patricia Anne Tinio, Rogelio Balagat\",\"doi\":\"10.1155/crdm/8810497\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Erythrodermic psoriasis (EP) is a severe type of psoriasis that requires immediate and effective treatment to prevent serious complications. Although recommended as first-line treatment for EP, conventional systemic disease-modifying antirheumatic drugs (csDMARDs) such as methotrexate and/or cyclosporine can sometimes be ineffective or undesirable, hence the use of biologics. However, in cases of refractory disease, biologics may be combined with methotrexate to boost efficacy and optimize outcomes without compromising safety and tolerability.\",\"PeriodicalId\":9630,\"journal\":{\"name\":\"Case Reports in Dermatological Medicine\",\"volume\":\"2025 \",\"pages\":\"8810497\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140818/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Case Reports in Dermatological Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/crdm/8810497\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crdm/8810497","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

红皮病型牛皮癣（EP）是一种严重类型的牛皮癣，需要立即和有效的治疗，以防止严重的并发症。虽然推荐作为EP的一线治疗，但传统的全身疾病改善抗风湿药物（csDMARDs）如甲氨蝶呤和/或环孢素有时可能无效或不可取，因此使用生物制剂。然而，在难治性疾病的情况下，生物制剂可以与甲氨蝶呤联合使用，在不影响安全性和耐受性的情况下提高疗效并优化结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Case of Erythrodermic Psoriasis Successfully Treated With Ixekizumab Combined With Low-Dose Methotrexate to Ensure Sustained Clearance: A Case Report.

Erythrodermic psoriasis (EP) is a severe type of psoriasis that requires immediate and effective treatment to prevent serious complications. Although recommended as first-line treatment for EP, conventional systemic disease-modifying antirheumatic drugs (csDMARDs) such as methotrexate and/or cyclosporine can sometimes be ineffective or undesirable, hence the use of biologics. However, in cases of refractory disease, biologics may be combined with methotrexate to boost efficacy and optimize outcomes without compromising safety and tolerability.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Case Reports in Dermatological Medicine Medicine-Dermatology

CiteScore

1.50

自引率

0.00%

发文量

审稿时长

15 weeks